These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28841282)

  • 1. Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors.
    Falchi F; Giacomini E; Masini T; Boutard N; Di Ianni L; Manerba M; Farabegoli F; Rossini L; Robertson J; Minucci S; Pallavicini I; Di Stefano G; Roberti M; Pellicciari R; Cavalli A
    ACS Chem Biol; 2017 Oct; 12(10):2491-2497. PubMed ID: 28841282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib.
    Bagnolini G; Milano D; Manerba M; Schipani F; Ortega JA; Gioia D; Falchi F; Balboni A; Farabegoli F; De Franco F; Robertson J; Pellicciari R; Pallavicini I; Peri S; Minucci S; Girotto S; Di Stefano G; Roberti M; Cavalli A
    J Med Chem; 2020 Mar; 63(5):2588-2619. PubMed ID: 32037829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.
    Roberti M; Schipani F; Bagnolini G; Milano D; Giacomini E; Falchi F; Balboni A; Manerba M; Farabegoli F; De Franco F; Robertson J; Minucci S; Pallavicini I; Di Stefano G; Girotto S; Pellicciari R; Cavalli A
    Eur J Med Chem; 2019 Mar; 165():80-92. PubMed ID: 30660828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An
    Myers SH; Poppi L; Rinaldi F; Veronesi M; Ciamarone A; Previtali V; Bagnolini G; Schipani F; Ortega Martínez JA; Girotto S; Di Stefano G; Farabegoli F; Walsh N; De Franco F; Roberti M; Cavalli A
    Eur J Med Chem; 2024 Feb; 265():116114. PubMed ID: 38194775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Rad51 sensitizes breast cancer cells with wild-type PTEN to olaparib.
    Zhao Q; Guan J; Zhang Z; Lv J; Wang Y; Liu L; Zhou Q; Mao W
    Biomed Pharmacother; 2017 Oct; 94():165-168. PubMed ID: 28759753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells.
    Malka MM; Eberle J; Niedermayer K; Zlotos DP; Wiesmüller L
    Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
    Guffanti F; Alvisi MF; Anastasia A; Ricci F; Chiappa M; Llop-Guevara A; Serra V; Fruscio R; Degasperi A; Nik-Zainal S; Bani MR; Lupia M; Giavazzi R; Rulli E; Damia G
    Br J Cancer; 2022 Jan; 126(1):120-128. PubMed ID: 34732853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51.
    Kaplan AR; Gueble SE; Liu Y; Oeck S; Kim H; Yun Z; Glazer PM
    Sci Transl Med; 2019 May; 11(492):. PubMed ID: 31092693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.
    Miyasaka A; Oda K; Ikeda Y; Wada-Hiraike O; Kashiyama T; Enomoto A; Hosoya N; Koso T; Fukuda T; Inaba K; Sone K; Uehara Y; Kurikawa R; Nagasaka K; Matsumoto Y; Arimoto T; Nakagawa S; Kuramoto H; Miyagawa K; Yano T; Kawana K; Osuga Y; Fujii T
    BMC Cancer; 2014 Mar; 14():179. PubMed ID: 24625059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRIP1 cooperates with BRCA2 to drive the nuclear enrichment of RAD51 and to facilitate homologous repair upon DNA damage induced by chemotherapy.
    Sun H; Zhou R; Zheng Y; Wen Z; Zhang D; Zeng D; Wu J; Huang Z; Rong X; Huang N; Sun L; Bin J; Liao Y; Shi M; Liao W
    Oncogene; 2021 Aug; 40(34):5342-5355. PubMed ID: 34262130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
    Chao OS; Goodman OB
    Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.
    Barber LJ; Sandhu S; Chen L; Campbell J; Kozarewa I; Fenwick K; Assiotis I; Rodrigues DN; Reis Filho JS; Moreno V; Mateo J; Molife LR; De Bono J; Kaye S; Lord CJ; Ashworth A
    J Pathol; 2013 Feb; 229(3):422-9. PubMed ID: 23165508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCAness revisited.
    Lord CJ; Ashworth A
    Nat Rev Cancer; 2016 Feb; 16(2):110-20. PubMed ID: 26775620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A small-molecule inhibitor of the BRCA2-RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell death.
    Scott DE; Francis-Newton NJ; Marsh ME; Coyne AG; Fischer G; Moschetti T; Bayly AR; Sharpe TD; Haas KT; Barber L; Valenzano CR; Srinivasan R; Huggins DJ; Lee M; Emery A; Hardwick B; Ehebauer M; Dagostin C; Esposito A; Pellegrini L; Perrior T; McKenzie G; Blundell TL; Hyvönen M; Skidmore J; Venkitaraman AR; Abell C
    Cell Chem Biol; 2021 Jun; 28(6):835-847.e5. PubMed ID: 33662256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA2 deficiency increases sensitivity of medulloblastoma to Olaparib by inhibiting RAD51-mediated DNA damage repair system.
    Yu J; Zhang C; Shi W; Rui H; Li H
    Clin Transl Oncol; 2022 May; 24(5):919-926. PubMed ID: 35001340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olaparib for the treatment of breast cancer.
    Robert M; Frenel JS; Gourmelon C; Patsouris A; Augereau P; Campone M
    Expert Opin Investig Drugs; 2017 Jun; 26(6):751-759. PubMed ID: 28395540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
    Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
    Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional characterization of EMSY gene amplification in human cancers.
    Wilkerson PM; Dedes KJ; Wetterskog D; Mackay A; Lambros MB; Mansour M; Frankum J; Lord CJ; Natrajan R; Ashworth A; Reis-Filho JS
    J Pathol; 2011 Sep; 225(1):29-42. PubMed ID: 21735447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Short BRCA2-Derived Cell-Penetrating Peptide Targets RAD51 Function and Confers Hypersensitivity toward PARP Inhibition.
    Trenner A; Godau J; Sartori AA
    Mol Cancer Ther; 2018 Jul; 17(7):1392-1404. PubMed ID: 29654063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.